thinkstockApril 16, 2015: Markets opened lower on Thursday before climbing above the break-even line in the mid-afternoon. Crude oil futures rose to another year-to-date high today and three hot IPOs buoyed investors…
thinkstockApril 14, 2015: Markets opened higher on again on Tuesday but all three major indexes slipped below the breakeven line soon thereafter. The S&P 500 and the DJIA pulled back into positive…
The 30-year Treasury Bond yields only about 2.5% and, amazingly, more than half of the 30 Dow Jones Industrial Average stocks are yielding more than that.
SunTrust Robinson Humphrey analysts expect the pharmaceutical industry to outperform in 2015, driven in part by a solid new product cycle and an attractive five-year growth rate.
thinkstockMarch 18, 2015: Markets opened lower on Wednesday and bided its time below the break-even line until just after 2 p.m. and the FOMC’s announcement that it would no longer wait patiently…
A new research report from SunTrust Robinson Humphrey is very positive on pharmaceuticals, and the analysts expect the sector to outperform this year.
With AT&T dropped from the Dow in favor of Apple, investors may be wondering which Dow stocks could get booted from the index next.
thinkstock February 9, 2015: Markets opened lower on Monday following remarks by Greece’s new president that rattled traders. There was no U.S. economic data out today. Shortly before the closing bell the…
If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today.
Merck reported largely in-line fourth-quarter financial results Wednesday before the U.S. markets opened.
Chris Lange 24/7 Wall St. has put together a preview of some of the larger companies reporting quarterly results in the coming week.
Merck shares posted a new 52-week high last Tuesday and closed Friday less than a buck from that high. Year to date, Its shares are up 11%.
One key consideration for the year ahead is that the Pfizer of 2016 or 2017 is likely to be night and day different from the Pfizer of 2005.
One key consideration for the year ahead is Merck's acquisitions of Idenix and Cubist Pharmaceuticals to expand its product offerings
Paul Ausick One key consideration for the year ahead is that Johnson & Johnson raised its dividends again and managed to have upside performance above what was expected.
